It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NEOG’s FA Score shows that 1 FA rating(s) are green whileVCYT’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NEOG’s TA Score shows that 6 TA indicator(s) are bullish while VCYT’s TA Score has 5 bullish TA indicator(s).
NEOG (@Medical Specialties) experienced а -10.04% price change this week, while VCYT (@Medical Specialties) price change was -1.48% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.23%. For the same industry, the average monthly price growth was -2.87%, and the average quarterly price growth was -6.14%.
NEOG is expected to report earnings on Dec 17, 2024.
VCYT is expected to report earnings on Mar 03, 2025.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
NEOG | VCYT | NEOG / VCYT | |
Capitalization | 3.42B | 1.66B | 205% |
EBITDA | 189M | -49.41M | -383% |
Gain YTD | -27.399 | 30.643 | -89% |
P/E Ratio | 150.80 | N/A | - |
Revenue | 919M | 361M | 255% |
Total Cash | 230M | 216M | 106% |
Total Debt | 889M | 12.6M | 7,056% |
NEOG | VCYT | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 16 | 34 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 96 Overvalued | 40 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 74 | |
SMR RATING 1..100 | 87 | 88 | |
PRICE GROWTH RATING 1..100 | 57 | 40 | |
P/E GROWTH RATING 1..100 | 3 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
VCYT's Valuation (40) in the Biotechnology industry is somewhat better than the same rating for NEOG (96) in the Medical Specialties industry. This means that VCYT’s stock grew somewhat faster than NEOG’s over the last 12 months.
VCYT's Profit vs Risk Rating (74) in the Biotechnology industry is in the same range as NEOG (100) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to NEOG’s over the last 12 months.
NEOG's SMR Rating (87) in the Medical Specialties industry is in the same range as VCYT (88) in the Biotechnology industry. This means that NEOG’s stock grew similarly to VCYT’s over the last 12 months.
VCYT's Price Growth Rating (40) in the Biotechnology industry is in the same range as NEOG (57) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to NEOG’s over the last 12 months.
NEOG's P/E Growth Rating (3) in the Medical Specialties industry is significantly better than the same rating for VCYT (100) in the Biotechnology industry. This means that NEOG’s stock grew significantly faster than VCYT’s over the last 12 months.
NEOG | VCYT | |
---|---|---|
RSI ODDS (%) | 3 days ago62% | 3 days ago90% |
Stochastic ODDS (%) | 3 days ago61% | 3 days ago82% |
Momentum ODDS (%) | 3 days ago55% | 3 days ago84% |
MACD ODDS (%) | 3 days ago57% | 3 days ago86% |
TrendWeek ODDS (%) | 3 days ago74% | 3 days ago84% |
TrendMonth ODDS (%) | 3 days ago75% | 3 days ago81% |
Advances ODDS (%) | 7 days ago69% | 11 days ago75% |
Declines ODDS (%) | 3 days ago75% | 3 days ago84% |
BollingerBands ODDS (%) | 3 days ago76% | 3 days ago84% |
Aroon ODDS (%) | 3 days ago71% | 3 days ago87% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
GTMIX | 15.15 | 0.02 | +0.13% |
GMO International Opportunistic Val III | |||
MIZIX | 8.41 | -0.06 | -0.71% |
MassMutual International Eq I | |||
GSQTX | 43.34 | -0.38 | -0.87% |
Goldman Sachs Small Cap Value Inv | |||
VSMAX | 118.05 | -1.27 | -1.06% |
Vanguard Small Cap Index Adm | |||
SGRKX | 44.77 | -0.94 | -2.06% |
Allspring Growth Admin |
A.I.dvisor indicates that over the last year, NEOG has been loosely correlated with CRL. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if NEOG jumps, then CRL could also see price increases.
Ticker / NAME | Correlation To NEOG | 1D Price Change % | ||
---|---|---|---|---|
NEOG | 100% | -0.27% | ||
CRL - NEOG | 47% Loosely correlated | -4.65% | ||
AZTA - NEOG | 45% Loosely correlated | -2.62% | ||
VCYT - NEOG | 44% Loosely correlated | -2.97% | ||
MASS - NEOG | 44% Loosely correlated | +0.42% | ||
TWST - NEOG | 43% Loosely correlated | -5.31% | ||
More |
A.I.dvisor indicates that over the last year, VCYT has been closely correlated with NTLA. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if VCYT jumps, then NTLA could also see price increases.
Ticker / NAME | Correlation To VCYT | 1D Price Change % | ||
---|---|---|---|---|
VCYT | 100% | -2.97% | ||
NTLA - VCYT | 69% Closely correlated | -7.61% | ||
VCEL - VCYT | 60% Loosely correlated | -0.49% | ||
AXON - VCYT | 58% Loosely correlated | -0.86% | ||
DNA - VCYT | 57% Loosely correlated | -12.86% | ||
ABCL - VCYT | 55% Loosely correlated | -3.99% | ||
More |